Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/11/2861393/29248/en/Anavex-Life-Sciences-to-Present-at-the-Noble-Capital-Markets-Virtual-Healthcare-Equity-Conference.html
https://www.globenewswire.com/news-release/2024/03/18/2847701/29248/en/Anavex-Life-Sciences-Initiates-Placebo-Controlled-U-S-Phase-2-Clinical-Trial-of-ANAVEX-3-71-in-Schizophrenia.html
https://www.globenewswire.com//news-release/2024/02/26/2835035/29248/en/Anavex-Life-Sciences-to-Present-at-the-44th-Annual-TD-Cowen-Health-Care-Conference.html
https://www.globenewswire.com//news-release/2024/02/07/2825082/29248/en/Anavex-Life-Sciences-Reports-Fiscal-2024-First-Quarter-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/01/24/2815160/29248/en/Anavex-Life-Sciences-Reports-Publication-of-ANAVEX-3-71-in-Clinical-Journal-Confirming-Pharmacokinetic-Dose-Proportionality-of-ANAVEX-3-71-in-Humans.html
https://www.globenewswire.com//news-release/2024/01/16/2809762/29248/en/Anavex-Life-Sciences-Announces-U-S-Phase-2-Clinical-Trial-of-ANAVEX-3-71-in-Schizophrenia.html
https://www.globenewswire.com//news-release/2024/01/08/2805328/29248/en/Anavex-Life-Sciences-Announces-Grant-of-U-S-Patent-Covering-Blarcamesine-ANAVEX-2-73-for-Treatment-of-Neurodevelopmental-Disorders.html
https://endpts.com/anavexs-experimental-drug-fails-rett-syndrome-study-stock-falls/
https://www.globenewswire.com//news-release/2024/01/03/2803192/29248/en/Anavex-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/20/2799175/29248/en/Anavex-Announces-First-Entire-Clinical-Gene-Pathway-Data-of-ANAVEX-2-73-from-AVATAR-Study-in-Patients-with-Rett-Syndrome.html